|
Impact Of Decreasing Copayments On Medication Adherence Within A Disease Management Environment
Michael E. Chernew,
Mayur R. Shah,
Arnold Wegh,
Stephen N. Rosenberg,
Iver A. Juster,
Allison B. Rosen,
Michael C. Sokol,
Kristina Yu-Isenberg and
A. Mark Fendrick
This paper estimates the effects of a large employer’s value-based insurance initiative designed to improve adherence to recommended treatment regimens. The intervention reduced copayments for five chronic medication classes in the context of a disease management (DM) program. Compared to a control employer that used the same DM program, adherence to medications in the value-based intervention increased for four of five medication classes, reducing nonadherence by 7–14 percent. The results demonstrate the potential for copayment reductions for highly valued services to increase medication adherence above the effects of existing DM programs.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
A. S. Kesselheim, A. S. Misono, and W. H. Shrank
Equivalence of Generic and Brand-Name Drugs for Cardiovascular Disease--Reply
JAMA,
April 22, 2009;
301(16):
1655 - 1656.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. K. Choudhry
Copayment Levels and Medication Adherence: Less Is More
Circulation,
January 27, 2009;
119(3):
365 - 367.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Greene, J. Hibbard, J. F. Murray, S. M. Teutsch, and M. L. Berger
The Impact Of Consumer-Directed Health Plans On Prescription Drug Use
Health Aff.,
July 1, 2008;
27(4):
1111 - 1119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Schoen, S. R. Collins, J. L. Kriss, and M. M. Doty
How Many Are Underinsured? Trends Among U.S. Adults, 2003 And 2007
Health Aff.,
July 1, 2008;
27(4):
w298 - w309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
